TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06581380: A Multicenter, Randomized, Positive-Controlled, Open-label, Phase 3 Study of JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Sponsor: JenKem Technology Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 394 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT06581380 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06581380 Rescue Dossier →